信必可都保治疗轻中度哮喘临床疗效观察  

Effects of symbicort turbuhaler in mild and moderate patients with bronchial asthma

作　　者：胡斯明[1] 罗雅玲[1] 

机构地区：[1]广州南方医院呼吸内科,510515

出　　处：《临床肺科杂志》2008年第9期1125-1126,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的评价信必可都保在治疗轻、中度支气管哮喘的临床疗效及安全性。方法对我院30例临床诊断哮喘的轻中度患者应用信必可都保吸入治疗,治疗后4、12周测定第1秒用力呼气容量(FEV1)、FEV1占预计值的百分比(FEV1%)、呼气50%用力肺活量时的流速(FEF50%)和峰值流速(PEF),观察临床疗效,进行治疗前后对比研究。结果30例中临床控制25例(83.3%),显效3例(10%),好转2例(6.7%)。治疗后4周、12周患者哮喘症状较治疗前明显改善(P<0.05)。治疗后4周、12周患者肺功能监测指标FEV1、FEV1%、FEF50%、PEF较治疗前明显增加(P<0.05);但治疗后4周与治疗后12周之间无统计学差异。结论信必可都保吸入治疗轻中度哮喘起效迅速、疗效确切、安全、副作用小、患者依从性好,值得临床推广应用。Objective To investigate the efficacy and safety of symbicort turbuhaler in the treatment of mild and moderate patients with bronchial asthma.Methods 30 cases treated by inhalation of symbicort turbuhaler,FEV1、FEV1%、FEF50%、PEF were detected 4 weeks and 12 weeks after treatment.The clinical efficacy was observed.Results In 30 cases,25 cases（83.3%）were clinically controlled,3 cases（10%）had effective treatment,2 cases（6.7%）had improvement.The symptoms of asthma improved and FEV1、FEV1%、FEF50%、PEF increased significantly after 4 weeks and 12 weeks treatment compared with：before treatment.There was no significant difference between 4 weeks and 12 weeks after treatment.Conclusions It was quick and safe.Little side-effect was observed using inhalation symbicort turbuhaler in treating mild and moderate patients with bronchial asthma.Patients show good compliances.It is worthy of being applied more in clinical practice.

关 键 词：哮喘 信必可都保 临床分析 疗效 

分 类 号：R562.25[医药卫生—呼吸系统] R725.622.5[医药卫生—内科学]